Inhibition of Cytochromes P450: Existing and New Promising Therapeutic Targets

References

• Anderson J. L., Chapman S. K. Ligand probes for heme proteins. Dalton Trans. 2005; 13–24
   PubMed Web of Science ®Google Scholar
• Angelastro M. R., Laughlin M. E., Schatzman G. L., Bey P., Blohm T. R. 17,-(Cyclopropylamino)-Androst-5-en-3,-ol, a Selective Mechanism-Based Inhibitor of Cytochrome P45017alpha (Steroid 17alpha-hydroxylase/C17, 20Lyase). Biochem. Biophys. Res. Commun. 1989; 162: 1571–1577
   PubMed Web of Science ®Google Scholar
• Attard G., Sarker D., Reid A., Molife R., Parker C., de Bono J. S. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. British Journal of Cancer 2006; 95: 767–774
   PubMed Web of Science ®Google Scholar
• Ayub M., Level M. Inhibition of Testicular 17α-hydroxylase and 17, 20-Lyase but not 3-Hydroxysteroid Dehydrogenase-Isomerase or 17-Hydroxysteroid Oxidoreductase by Ketoconazole and Other Imidazole drugs. J. Steroid Biochem. 1987; 28: 521–531
   PubMedGoogle Scholar
• Barrie S. E., Rowlands M. G., Foster A. B., Jarman M. Inhibition of 17α-hydroxylase/C17, 20Lyase by bifluranol and its analogues. J. Steroid Biochem. 1989; 33: 1191–1195
   PubMedGoogle Scholar
• Barrie S. E., Potter G. A., Goddard P. M., Haynes B. P., Dowsett M., Jarman M. Pharmacology of Novel Steroidal Inhibitors of Cytochrome P45017alpha (17alpha-Hydroxylase/C17, 20 Lyase. J. Steroid Biochem. Mol. Biol. 1994; 50: 267–273
   PubMed Web of Science ®Google Scholar
• Belkina N. V., Lisurek M., Ivanov A. S., Bernhardt R. Modelling of three-dimensional structures of cytochromes P450 11B1 and 11B2. J. Inorg. Biochem. 2001; 87: 197–207
   PubMed Web of Science ®Google Scholar
• Boelsterli U. A. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 2003; 192: 307–322
   PubMed Web of Science ®Google Scholar
• Böttner B., Bernhardt R. Changed ratios of glucocorticoids/mineralocorticoids caused by point mutations in the putative I-helix regions of CYP11B1 and CYP11B2. Endocr. Res. 1996a; 4: 455–461
   Google Scholar
• Böttner B., Schrauber H., Bernhardt R. Engineering a mineralocorticoid- to a glucocorticoid-synthesizing cytochrome P450. J. Biol. Chem. 1996b; 271: 8028–8033
   PubMed Web of Science ®Google Scholar
• Böttner B., Denner K., Bernhardt R. Conferring novel aldosterone synthesis to human CYP11B1 by replacing key amino acid residues for CYP11B2 specific ones. Eur. J. Biochem. 1998; 252: 458–466
   PubMedGoogle Scholar
• www.fda.gov/cder/livertox/presentations2007.htm, Bonkovsky, H. L. (2007). AASLD-FDA-NiH-PhRMA Hepatotoxicity Meeting
   Google Scholar
• Bostwick D. G., Cooner W. H., Denis L., Jones G. W., Scardino P. W., Murphy G. P. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 1992; 70: 291–301
   PubMed Web of Science ®Google Scholar
• Brilla C. G. Aldosterone and moyocardial fibrosis in heart failure. Herz 2000; 25: 299–306
   PubMed Web of Science ®Google Scholar
• Brown A. J., Ritter C., Slatopolsky E. Vitamin D. Am. J. Physiol. 1999; 277: 157–175
   PubMed Web of Science ®Google Scholar
• Brueggemeier R. W., Hackett J. C., Diaz-Cruz E. S. Aromatase inhibitors in the treatment of breast cancer. Endocrine Reviews 2005; 26: 331–345
   PubMed Web of Science ®Google Scholar
• Bureik M., Hübel K., Dragan C.-A., Scher J., Becker H., Lenz N., Bernhardt R. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11β-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension. Molecular and Cellular Endocrinology 2004; 217: 249–254
   PubMed Web of Science ®Google Scholar
• Cai W., Counsell R. E., Schteingart D. E., Sinsheimer J. E., Vaz A. D. N., Wotring L. L. Adrenal proteins bound by a reactive intermediate of mitotane. Cancer Chemother. Pharmacol. 1997; 39: 537–540
   PubMed Web of Science ®Google Scholar
• Chen P., Guo M., Wygle D., Edwards P. A., Falck J. R., Roman R. J., Scicli A. G. Inhibitors of Cytochrome P450 4A Suppress Angiogenic Responses. Amer. J. Pathol. 2005; 166: 615–624
   PubMed Web of Science ®Google Scholar
• De Coster R., Wouters W., Bruynseels J. P-450 dependent enzymes as targets for prostate cancer therapy. J. Steroid Biochem. Mol. Biol. 1996; 56: 133–143
   PubMed Web of Science ®Google Scholar
• Delyani J. A. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 2000; 57: 1408–1411
   PubMed Web of Science ®Google Scholar
• Denner K., Doehmer J., Bernhardt R. Cloning of CYP11B1 and CYP11B2 from normal human adrenals and their functional expression in COS- and V79 Chinese Hamster cells. Endocr. Res. 1995a; 21: 443–448
   PubMed Web of Science ®Google Scholar
• Denner K., Vogel R., Schmalix W., Doehmer J., Bernhardt R. Cloning and stable expression of the human mitochondrial cytochrome P45011B1 cDNA in V79 chinese hamster cells and their application for testing of potential inhibitors.”. Pharmacogenetics 1995b; 5: 89–96
   PubMedGoogle Scholar
• Denner K., Bernhardt R. Inhibition studies of steroid conversions mediated by human CYP11B1 and CYP11B2 expressed in cell cultures. Oxygen Homeostasis and its Dynamics. Springer-Verlag, Tokyo, Berlin, Heidelberg, New York 1998; 231–236
   Google Scholar
• Dogne J. M., de Leval X., Benoit P., Rolin S., Pirotte B., Masereel B. Therapeutic potential of thromboxane inhibitors in asthma. Expert. Opin. Investig. Drugs 2002; 11: 275–281
   Web of Science ®Google Scholar
• De With K., Steib-Bauert M., Knoth H., Dörje F., Strehl E., Rothe U., Maier L., Kern W. V. Hospital use of systemic antifungal drugs. BMC Clin. Pharmacol. 2005; 5: 1, http://www.biomedcentral.com/1472-6904/5/1
   PubMedGoogle Scholar
• Ehmer P. B., Bureik M., Bernhardt R., Muller U., Hartmann R. W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells. J. Steroid Biochem. Mol. Biol. 2002; 81: 173–179
   PubMed Web of Science ®Google Scholar
• Ekins S., Mankowski D. C., Hoover D. J., Lawton M. P., Treadway J. L., Harwood H. J. Three Dimensional-Quantitative Structure Activity Relationship Analysis of Human CYP51 Inhibitors. Drug. Metab. Dispos. 2007; 35: 493–500
   PubMed Web of Science ®Google Scholar
• Ekroos M., Sjögren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. 2006; 103: 13682–13687, U.S.A.
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Wu Z. L., Bartelson C. J. Function of human cytochrome P450s: characterization of the orphans. Biochem. Biophys. Res. Commun. 2005; 338: 465–469
   PubMed Web of Science ®Google Scholar
• Hakki T., Bernhardt R. CYP 17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacology & Therapeutics 2006; 111: 27–52
   PubMed Web of Science ®Google Scholar
• Hartmann R. W., Ehmer P. B., Haidar S., Hector M., Jose J., Klein C. D. P., Seidel S. B., Sergejew T. F., Wachall B. G., Wächter G. A., Zhuang Y. Inhibition of CYP17, a new strategy of the Treatment of prostate cancer. Arch. Pharm. Med. Chem. 2002; 4: 119–128
   Web of Science ®Google Scholar
• Howell A., Howell S. J., Clarke R., Anderson E. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (ALs) now fit into breast cancer treatment algorithms?. J. Steroid Biochem. Mol. Biol. 2001; 79: 227–237
   PubMed Web of Science ®Google Scholar
• Jarman M., Barrie S. E., Deadman J. J., Houghton J., McCague R. Hydroxyperfluoroazobenzenes: Novel Inhibitors of Enzymes of Androgen Biosynthesis. J. Med. Chem. 1990; 33: 2452–2455
   PubMed Web of Science ®Google Scholar
• Jonat W., Mundhenke C. The FACE Trial: Letrozole or Anastrozole as Initial Adjuvant Therapy?. Cancer Invest. 2007a; 25: 14–18
   PubMed Web of Science ®Google Scholar
• Jonat W., Hilpert F., Kaufmann M. Aromatase inhibitors: a safety comparison. Expert Opinion on Drug Safety 2007b; 6: 165–174
   PubMed Web of Science ®Google Scholar
• Kahraman M., Sinishtaj S., Dolan P. M., Kensler T. W., Peleg S., Saha U., Chuang S. S., Bernstein G., Korczak B., Posner G. H. Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1 alpha,25-dihydroxyvitamin D(3). J. Med. Chem. 2004; 47: 6854–6863
   PubMed Web of Science ®Google Scholar
• Karlgren M., Ingelman-Sundberg M. Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy. Expert Opin. Ther. Targets 2007; 11: 61–67
   PubMed Web of Science ®Google Scholar
• Kent U. M., Jushchyshyn M. I., Hollenberg P. W. Mechanism-Based Inactivators as Probes of Cytochrome P450 Structure and Function. Curr. Drug Metab. 2001; 2: 215–243
   PubMed Web of Science ®Google Scholar
• http://www.prostate-cancer.org/education/andeprv/Lam_HDK.html, Lam, R. (2004). High Dose Ketoconazole Plus Hydrocortisone (HDK+ HC). PCRI InsightsNewsletter 7(2)
   Google Scholar
• Lepesheva G. I., Waterman M. R. Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochim. Biophys. Acta 2007; 1770: 467–477
   PubMed Web of Science ®Google Scholar
• Lijnen P., Petrov V. Induction of cardiac fibrosis by aldosterone. J. Mol. Cell. Cardiac. 2000; 32: 865–879
   PubMed Web of Science ®Google Scholar
• Ljubimov A. V., Grant M. B. P450 in the angiogenesis affair. Am. J. Pathol. 2005; 166: 341–344
   PubMed Web of Science ®Google Scholar
• Long B., Grigoryev D. N., Nnane I. P., Liu Y., Ling Y. Z., Brodie A. M. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res. 2000; 60: 6630–6640
   PubMed Web of Science ®Google Scholar
• MacFadyen R. J., Barr C. S., Struthers A. D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc. Res. 1997; 35: 30–34
   PubMed Web of Science ®Google Scholar
• Mantero F., Lucarelli G. Aldosterone antagonism in hypertension and heart failure. Ann. Endocrinol. 2000; 61: 52–60
   PubMed Web of Science ®Google Scholar
• McCague R., Rowlands M. G., Barrie S. E., Houghton J. Inhibition of Enzymes of Estrogen and Androgen Biosynthesis by Ester of 4-Pyridylacetic acid. J. Med. Chem. 1990; 33: 3050–3055
   PubMed Web of Science ®Google Scholar
• McFadyen M. C. E., Murray G. I. Cytochrome P450 1B1: a novel anticancer therapeutic target. Future Oncol. 2005; 1: 259–263
   PubMedGoogle Scholar
• McGurie W. L. Steroid hormone receptors in breast cancer treatment strategy. Recent Prog. Horm. Res. 1980; 36: 135–156
   PubMedGoogle Scholar
• Miller W. H. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 1998; 83: 1471–1482
   PubMed Web of Science ®Google Scholar
• Murray M. Review of: Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Breast Cancer Online 2004; 7(10), (www.bco.org):
   Google Scholar
• Nagpal S., Na S., Rathnachalam R. Noncalcemic Actions of Vitamin D Receptor Ligands. Endocrine Reviews 2005; 26: 662–687
   PubMed Web of Science ®Google Scholar
• Nakajin S., Takahashi K., Shinoda M. Inhibitory Effect and Spectral Changes on Pig Testicular Cytochrome P-450 (17αhydroxylase/C17, 20-lyase) by 20,-Hydroxy-C21-steroids. Yakugaku Zasshi 1988; 108: 1188–1195
   PubMed Web of Science ®Google Scholar
• Nakajin S., Takahashi K., Shinoda M. Inhibitory effect and Interaction of Stanozolol with Pig Testicular Cytochrome P-450 (17α-hydroxylase/C17, 20-Lyase). Chem. Pharm. Bull. (Tokyo) 1989; 37: 1855–1858
   PubMed Web of Science ®Google Scholar
• Njar V. C. O. Cytochrome P450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy. Mini Rev. Med. Chem 2002; 2: 261–269
   PubMed Web of Science ®Google Scholar
• Obermayer-Straub P., Strassburg C. P., Manns M. P. Target proteins in human autoimmunity: cytochromes P450 and UDP-glucuronyltransferases. Can. J. Gastroenterol. 2000; 14: 429–439
   PubMed Web of Science ®Google Scholar
• O'Donnell A., Judson I., Dowsett M., Raynaud F., Dearnaley D., Mason M., Harland S., Robbins A., Halbert G., Nutley B., Jarman M. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 2004; 90: 2317–2325
   PubMed Web of Science ®Google Scholar
• Overington J. P., Al-Lazikani B., Hopkins A. L. How many drug targets are there?. Nature Reviews Drug Discovery 2006; 5: 993–996
   PubMed Web of Science ®Google Scholar
• Pasqualini J. R., Chetrite G., Blacker C., Feinstein M. C., Delalonde L., Talbi M., Maloche C. Concentration of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 1996; 81: 1460–1464
   PubMed Web of Science ®Google Scholar
• Patel J., Khandelwal A., Chopra P., Handratta V., Njar V. Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents. Cancer Chemother. Pharmacol. 2007, Mar 8: (Epub ahead of print).
   Web of Science ®Google Scholar
• Patscheke H. Current concepts for a drug-induced inhibition of formation and action of thromboxane A2. Blut 1990; 60: 261–268
   PubMedGoogle Scholar
• Pitt B., Zannad F., Remme W. J., Cody R., Castaigne A., Peerez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldosterone Evaluation study Investigators. N. Engl. J. Med. 1999; 341: 709–717
   PubMed Web of Science ®Google Scholar
• Pitt B., Williams G., Remme W., Martinez F., Lopez-Sendon J., Zannad F., Neaton J., Roniker B., Hurley S., Burns D., Bittman R., Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc. Drugs Ther. 2001; 1: 79–87
   Web of Science ®Google Scholar
• Pitt B. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?. J. Card. Fail. 2002; 8: 491–493
   Web of Science ®Google Scholar
• Podust L. M., Stojan J., Poulos T. L., Waterman M. R. Substrate recognition sites in 14alpha-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51. J. Inorg. Biochem. 2001; 87: 227–235
   PubMed Web of Science ®Google Scholar
• Posner G. H., Crawford K. R., Yang H. W., Kahraman M., Jeon H. B., Li H., Lee J. K., Suh B. C., Hatcher M. A., Labonte T., Usera A., Dolan P. M., Kensler T. W., Peleg S., Jones G., Zhang A., Korczak B., Saha U., Chuang S. S. Potent, low-calcemic, selective inhibitors of CYP24 hydroxylase: 24-sulfone analogs of the hormone 1α,25-dihydroxyvitamin D3. J. Steroid Biochem. Mol. Biol. 2004; 89–90; 5–12
   Web of Science ®Google Scholar
• Potter G. A., Barrie S. E., Jarman M., Rowlands M. Novel Steroidal Inhibitors of Human Cytochrome P45017alpha (17α-Hydroxylase/C17–20 Lyase): Potential Agents for the Treatment of Prostatic Cancer. J. Med. Chem. 1996; 38: 2463–2471
   Web of Science ®Google Scholar
• Ramires F. J., Sun Y., Weber K. T. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. J. Mol. Cell. Cardiol. 1998; 30: 475–483
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona C., Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006; 25: 1679–1691
   PubMed Web of Science ®Google Scholar
• Roos T. C., Jugert F. K., Merk H. F., Bickers D. R. Retinoid metabolism in the skin. Pharmacol. Rev 1998; 50: 315–333
   PubMed Web of Science ®Google Scholar
• Rowlands M. G., Barrie S. E., Chan F., Houghton J., Jarman M., McCague R., Potter G. A. Esters of 3-Pyridylacetic Acid that Combine Potent Inhibition of 17α-Hydroxylase/C17,20-Lyase (Cytochrome P45017R) with Resistance to Esterase hydrolysis. J. Med. Chem. 1995; 38: 4191–4197
   PubMed Web of Science ®Google Scholar
• Russ A. P., Lampel S. The druggable genome: an update. DDT 2005; 10: 1607–1610
   PubMed Web of Science ®Google Scholar
• Santen R. J., Samojlik E., Lipton A., Harvey H., Ruby E. R., Wells S. A., Kendall J. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer. 1977; 39: 2948–2958
   PubMed Web of Science ®Google Scholar
• Schuster I. Ergosterol Synthesis: The major Target in Antimycotic Therapy. Frontiers in Biotransformation, K. Ruckpaul, R. Rein. Akademie Verlag, Berlin 1993; 8: 147–185
   Google Scholar
• Schuster I. The interaction of representative members from two classes of antimycotics–the azoles and the allylamines–with cytochromes P-450 in steroidogenic tissues and liver. Xenobiotica 1985; 15: 529–546
   PubMed Web of Science ®Google Scholar
• Schuster I., Egger H., Bikle D., Herzig G., Reddy G. S., Stuetz A., Stuetz P., Vorisek G. Selective inhibition of vitamin D hydroxylases. Steroids 2001; 66: 409–422
   PubMed Web of Science ®Google Scholar
• Schuster I., Astecker N., Egger H., Herzig G., Reddy G. S., Schuessler M., Vorisek G., Wachter C. Inhibitors of vitamin D-hydroxylases: mechanistic tools and therapeutic aspects. New Topics in Vitamin D Research, VD Stolzt. Nova Science Publishers, NY 2006; 67–144
   Google Scholar
• Schwarzel W. C., Kruggel W. G., Brodie H. J. Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta. Endocrinology 1973; 92: 866–880
   PubMed Web of Science ®Google Scholar
• Sheehan D. J., Hitchcock C. A., Sibley C. M. Current and Emerging Azole Antifungal Agents. Clin. Microbiol. Rev. 1999; 12: 40–79
   PubMed Web of Science ®Google Scholar
• Simpson E. R., Misso M., Hewit K. N., Hill R. A., Boon W. C., Jones M. E., Kovacic A., Zhou J., Clyne C. D. Estrogen – the Good, the Bad, and the Unexpected. Endocrine Reviews 2005; 26: 322–330
   PubMed Web of Science ®Google Scholar
• Simpson E. R., Dowsett M. Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog. Horm. Res. 2002; 57: 317–338
   PubMedGoogle Scholar
• Small E. J., Baron A., Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with “advanced” prostate carcinoma. Cancer 1997; 80: 1755–1759
   PubMed Web of Science ®Google Scholar
• Soberman J. E., Weber K. T. Spironolactone in congestive heart failure. Curr. Hypertens Rep. 2000; 2: 451–456
   PubMedGoogle Scholar
• Sonino N., Boscaro M. Medical therapy for Cushing's disease. Endocrinal Metab. Clin. North Am. 1999; 28: 211–222
   PubMed Web of Science ®Google Scholar
• Stearns M. E., Wang M., Fudge K. Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity. Cancer Res. 1993; 53: 3073–3077, Erratum in: Cancer Res. 53:5831 (1993).
   PubMed Web of Science ®Google Scholar
• Stowasser M., Gordon R. D., Tunny T. J., Klemm S. A., Finn W. L., Krek A. L. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin. Exp. Pharmacol. Physiol. 1992; 19: 319–322
   PubMed Web of Science ®Google Scholar
• Trachtenberg J. Ketoconazole Therapy in Advanced Prostatic Cancer. J. Urol. 1984; 132: 61–63
   PubMed Web of Science ®Google Scholar
• Ulmschneider S., Muller-Vieira U., Mitrenga M., Hartmann R. W., Oberwinkler-Marchais S., Klein C. D., Bureik M., Bernhardt R., Antes I., Lengauer T. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J. Med. Chem. 2005a; 48: 1796–1805
   PubMed Web of Science ®Google Scholar
• Ulmschneider S., Muller-Vieira U., Klein C. D., Antes I., Lengauer T., Hartmann R. W. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J. Med. Chem. 2005b; 48: 1563–1575
   PubMed Web of Science ®Google Scholar
• Van den Bossche H., Willemsens G., Bellens D., Janssen P. A. Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis. Biochem. Pharmacol. 1992a; 43: 739–744
   PubMed Web of Science ®Google Scholar
• Van den Bossche H. Inhibitors of P450-dependend steroid biosynthesis: from research to medical treatment. J. Steroid. Biochem. Mol. Biol. 1992b; 43: 1003–1021
   PubMed Web of Science ®Google Scholar
• Van Wauwe J., Van Nyen G., Coene M. C., Stoppie P., Cools W., Goossens J., et al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J. Pharmacol. Exper. Ther. 1992; 261: 773–779
   PubMed Web of Science ®Google Scholar
• Williams G., Kerle D. J., Doble A., Dunlop H., Smith C., Allen J., Yeo T., Bloom S. R. Objective Responses to Ketoconazole Therapy in Patients with Relapsed Progressive Prostate Cancer. Br J. Urol. 1986; 58: 45–51
   PubMedGoogle Scholar
• White J. A., Beckett-Jones B., Guo Y-D, Dilworth F. J., Bonasoro J., Jones G., Petkovich M. cDNA Cloning of Human Retinoic Acid-metabolizing Enzyme (hP450RAI) Identifies a Novel Family of Cytochromes P450 (CYP26). J. Biol. Chem 1997; 272: 18538–18541
   PubMed Web of Science ®Google Scholar
• Young M., Funder J. W. Aldosterone and heart. Trends Endocr. Metab. 2000; 11: 224–226
   PubMed Web of Science ®Google Scholar
• Zhou S., Chan E., Lim L. Y., Boelsterli U. A., Li S. C., Wang J., Zhang Q., Xu A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug. Metab. 2004; 5: 415–442
   PubMed Web of Science ®Google Scholar
• Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence?. Brit. J. Nutr. 2003; 89: 552–572
   PubMed Web of Science ®Google Scholar